Tumoristatic Effects of Anti-CD40 MAb-activated Macrophages Involve Nitric Oxide and Tumour Necrosis Factor-alpha

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2006 Jun 15

PMID 16771862

Citations 32

Authors

Hillary D Lum

Ilia N Buhtoiarov

Brian E Schmidt

Gideon Berke

Donna M Paulnock

Paul M Sondel

Alexander L Rakhmilevich

Affiliations

Soon will be listed here.

Abstract

Effector cells of the innate immune system have diverse functions that can result in tumour inhibition or tumour progression. Activation of macrophages by CD40 ligation has been shown to induce antitumour effects in vitro and in vivo. Here we investigated the role of nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) as mediators in the tumoristatic effects of murine peritoneal macrophages activated with agonistic anti-CD40 monoclonal antibody (alphaCD40) alone and following further stimulation with bacterial lipopolysaccharide (LPS). We found that macrophages activated in vivo by alphaCD40 exhibited tumoristatic activity in vitro against B16 melanoma cells; the tumoristatic effect correlated with the level of NO production and was enhanced by LPS. Use of the NO inhibitor L-nitro-arginine-methyl esterase (L-NAME) and evaluation of macrophages from inducible NO synthase (iNOS)-knockout (KO) mice following alphaCD40 activation showed reduced tumoristatic activity. CD40 ligation enhanced expression of TNF-alpha. Macrophage tumoristatic activity following alphaCD40 treatment was reduced by TNF-alpha mAb or use of macrophages from TNF-alpha-KO mice. However, further stimulation of alphaCD40-activated macrophages with LPS resulted in strong tumoristatic activity that was much less dependent on NO or TNF-alpha. Taken together, these results suggest that NO and TNF-alpha are involved in, but not solely responsible for, the antitumour effects of macrophages after activation by CD40 ligation.

Citing Articles

IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis.

Vadevoo S, Kang Y, Gunassekaran G, Lee S, Park M, Jo D Theranostics. 2024; 14(6):2605-2621.

PMID: 38646639 PMC: 11024855. DOI: 10.7150/thno.92672.

A metabolic perspective on nitric oxide function in melanoma.

Jimenez J, Dubey P, Carter B, Koomen J, Markowitz J Biochim Biophys Acta Rev Cancer. 2023; 1879(1):189038.

PMID: 38061664 PMC: 11380350. DOI: 10.1016/j.bbcan.2023.189038.

Tumor-associated myeloid cells in cancer immunotherapy.

Cheng X, Wang H, Wang Z, Zhu B, Long H J Hematol Oncol. 2023; 16(1):71.

PMID: 37415162 PMC: 10324139. DOI: 10.1186/s13045-023-01473-x.

Dynamic CD8 T Cell Cooperation with Macrophages and Monocytes for Successful Cancer Immunotherapy.

Vermare A, Guerin M, Peranzoni E, Bercovici N Cancers (Basel). 2022; 14(14).

PMID: 35884605 PMC: 9318008. DOI: 10.3390/cancers14143546.

Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors.

Musick M, Yu X Immunol Res. 2022; 70(4):432-440.

PMID: 35486115 DOI: 10.1007/s12026-022-09277-w.

References

Turner J, Rakhmilevich A, Burdelya L, Neal Z, Imboden M, Sondel P . Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol. 2000; 166(1):89-94. DOI: 10.4049/jimmunol.166.1.89. View

Bingaman A, Pearson T, Larsen C . The role of CD40L in T cell-dependent nitric oxide production by murine macrophages. Transpl Immunol. 2001; 8(3):195-202. DOI: 10.1016/s0966-3274(00)00026-5. View

Coussens L, Werb Z . Inflammatory cells and cancer: think different!. J Exp Med. 2001; 193(6):F23-6. PMC: 2193419. DOI: 10.1084/jem.193.6.f23. View

Bingle L, Brown N, Lewis C . The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196(3):254-65. DOI: 10.1002/path.1027. View

Netea M, van der Meer J, Verschueren I, Kullberg B . CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. Eur J Immunol. 2002; 32(5):1455-63. DOI: 10.1002/1521-4141(200205)32:5<1455::AID-IMMU1455>3.0.CO;2-C. View

Tsung K, Dolan J, Tsung Y, Norton J . Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002; 62(17):5069-75. View

Hume D, Ross I, Himes S, Sasmono R, Wells C, Ravasi T . The mononuclear phagocyte system revisited. J Leukoc Biol. 2002; 72(4):621-7. View

Klimp A, de Vries E, Scherphof G, Daemen T . A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol. 2002; 44(2):143-61. DOI: 10.1016/s1040-8428(01)00203-7. View

Matsuura M, Saito S, Hirai Y, Okamura H . A pathway through interferon-gamma is the main pathway for induction of nitric oxide upon stimulation with bacterial lipopolysaccharide in mouse peritoneal cells. Eur J Biochem. 2003; 270(19):4016-25. DOI: 10.1046/j.1432-1033.2003.03792.x. View

10.

Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G . Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2003; 53(2):64-72. PMC: 11032848. DOI: 10.1007/s00262-003-0443-2. View

11.

Cappello P, Caorsi C, Bosticardo M, De Angelis S, Novelli F, Forni G . CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J Leukoc Biol. 2003; 75(1):135-42. DOI: 10.1189/jlb.0403146. View

12.

Schroder K, Hertzog P, Ravasi T, Hume D . Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2003; 75(2):163-89. DOI: 10.1189/jlb.0603252. View

13.

Burger D, Molnarfi N, Gruaz L, Dayer J . Differential induction of IL-1beta and TNF by CD40 ligand or cellular contact with stimulated T cells depends on the maturation stage of human monocytes. J Immunol. 2004; 173(2):1292-7. DOI: 10.4049/jimmunol.173.2.1292. View

14.

Mantovani A, Allavena P, Sica A . Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004; 40(11):1660-7. DOI: 10.1016/j.ejca.2004.03.016. View

15.

Decker T, Lohmann-Matthes M, Gifford G . Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol. 1987; 138(3):957-62. View

16.

Hibbs Jr J, Taintor R, Vavrin Z, Rachlin E . Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun. 1988; 157(1):87-94. DOI: 10.1016/s0006-291x(88)80015-9. View

17.

Higuchi M, Higashi N, Taki H, Osawa T . Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J Immunol. 1990; 144(4):1425-31. View

18.

Liew F, Millott S, Parkinson C, Palmer R, Moncada S . Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol. 1990; 144(12):4794-7. View

19.

Klostergaard J, LEROUX M, Hung M . Cellular models of macrophage tumoricidal effector mechanisms in vitro. Characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro. J Immunol. 1991; 147(8):2802-8. View

20.

Cui S, Reichner J, Mateo R, ALBINA J . Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res. 1994; 54(9):2462-7. View